Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucas M A Goossens

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Pharmacoeconomics|March 14, 2012
Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issuesMaureen P M H Rutten-van Mölken, Lucas M A Goossens
International Journal of Nursing Studies|June 23, 2020
The risk of overestimating cost savings from hospital-at-home schemes: A literature reviewLucas M A Goossens, Pepijn Vemer, Maureen P M H Rutten-van Mölken
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 14, 2014
Not simply more of the same: distinguishing between patient heterogeneity and parameter uncertaintyPepijn Vemer, Lucas M A Goossens, Maureen P M H Rutten-van Mölken
Vaccine|January 25, 2008
The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the NetherlandsLucas M A Goossens, Baudouin Standaert, Nico Hartwig, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 15, 2025
Characterizing a heterogeneous chronic patient population for redesigning person-centred bundled payment models using risk-mitigating measuresSterre S Bour, Lucas M A Goossens, Maureen P M H Rutten-van Mölken
BMC Pulmonary Medicine|October 20, 2014
Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trialLucas M A Goossens, Inge Leimer, Norbert Metzdorf, et al.
Arthritis Care & Research|March 21, 2017
Cost-Utility Analysis of High Molecular Weight Hyaluronic Acid for Knee Osteoarthritis in Everyday Clinical Care in Patients at a Working Age: An Economic Evaluation of a Randomized Clinical TrialJob Hermans, Max Reijman, Lucas M A Goossens, et al.
Respiratory Medicine|March 29, 2011
Is the EQ-5D responsive to recovery from a moderate COPD exacerbation?Lucas M A Goossens, Michael C Nivens, Paul Sachs, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 20, 2012
Adjusting for COPD severity in database research: developing and validating an algorithmLucas M A Goossens, Christine L Baker, Brigitta U Monz, et al.
Journal of Abnormal Child Psychology|January 10, 2018
Multisystemic Therapy and Functional Family Therapy Compared on their Effectiveness Using the Propensity Score MethodHester V Eeren, Lucas M A Goossens, Ron H J Scholte, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Pharmacoeconomics|March 14, 2012
Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issuesMaureen P M H Rutten-van Mölken, Lucas M A Goossens
International Journal of Nursing Studies|June 23, 2020
The risk of overestimating cost savings from hospital-at-home schemes: A literature reviewLucas M A Goossens, Pepijn Vemer, Maureen P M H Rutten-van Mölken
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 14, 2014
Not simply more of the same: distinguishing between patient heterogeneity and parameter uncertaintyPepijn Vemer, Lucas M A Goossens, Maureen P M H Rutten-van Mölken
Vaccine|January 25, 2008
The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the NetherlandsLucas M A Goossens, Baudouin Standaert, Nico Hartwig, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 15, 2025
Characterizing a heterogeneous chronic patient population for redesigning person-centred bundled payment models using risk-mitigating measuresSterre S Bour, Lucas M A Goossens, Maureen P M H Rutten-van Mölken
BMC Pulmonary Medicine|October 20, 2014
Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trialLucas M A Goossens, Inge Leimer, Norbert Metzdorf, et al.
Arthritis Care & Research|March 21, 2017
Cost-Utility Analysis of High Molecular Weight Hyaluronic Acid for Knee Osteoarthritis in Everyday Clinical Care in Patients at a Working Age: An Economic Evaluation of a Randomized Clinical TrialJob Hermans, Max Reijman, Lucas M A Goossens, et al.
Respiratory Medicine|March 29, 2011
Is the EQ-5D responsive to recovery from a moderate COPD exacerbation?Lucas M A Goossens, Michael C Nivens, Paul Sachs, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 20, 2012
Adjusting for COPD severity in database research: developing and validating an algorithmLucas M A Goossens, Christine L Baker, Brigitta U Monz, et al.
Journal of Abnormal Child Psychology|January 10, 2018
Multisystemic Therapy and Functional Family Therapy Compared on their Effectiveness Using the Propensity Score MethodHester V Eeren, Lucas M A Goossens, Ron H J Scholte, et al.
Pageof 4